News

FFB Bancorp Reveals Q3 Financial Performance Insights

FFB Bancorp Reveals Q3 Financial Performance Insights

FFB Bancorp Third Quarter Financial Update

FFB Bancorp (OTCQX: FFBB), the parent company of FFB Bank, has recently shared its financial results for the third quarter. This update presents an overview of the bank's operational achievements, financial highlights, and strategic initiatives during the quarter.

Financial Highlights

Quarterly Performance Overview

In the third quarter, FFB Bancorp reported a net income of $6.24 million, translating to $2.06 per diluted share. This is a slight increase compared to the $6.04 million reported in the previous quarter. However, it marks a decline from $8.56 million in net income recorded during the same period last year.

For the first nine months of 2025, the company’s net income stood at $20.37 million, or $6.57 per diluted share, reflecting a decrease from the $24.43 million earned in the same timeframe last year, signaling an ongoing challenge in maintaining year-over-year performance levels.

Key Financial Metrics

  • Book value per common share increased by 6% to $60.04 compared to the prior quarter and rose 17% year-over-year.
  • Net interest margin (NIM) improved to 5.15%, reflecting a 6 basis point rise from the previous quarter and a 4 basis point improvement year-over-year.
  • Operating revenue decreased by 14% to $23.49 million from the previous quarter, and was down 8% from the same period last year.
  • Total assets increased by 2% quarter-over-quarter, totaling $1.50 billion, although a 1% decrease was noted compared to the same quarter of the previous year.
  • Total deposits reached $1.26 billion, which is a 2% increase from the prior quarter but a 2% decrease compared to the same time last year.

Strategic Developments

Leadership and Growth Initiatives

During the recent quarter, FFB Bancorp demonstrated continued commitment to its strategic growth plan. President & CEO Steve Miller noted that the hiring of a new Chief Banking Officer is set to enhance leadership and bolster sales performance. This role is intended to improve product cross-selling tactics and foster talent development, positioning the bank to seize future business opportunities.

Update on Stock Repurchase Program

The bank had previously announced a plan on January 22, 2025, to utilize up to $15 million to repurchase shares of its common stock. By September 30, 2025, the program had fully utilized the authorization, having repurchased 194,049 shares at an average price of $77.21. The stock repurchases represent roughly 7.73% of the total shareholders' equity as of the same date.

Income and Expense Trends

Non-Interest Expenses

Non-interest expenses in the third quarter were reported at $14.27 million, marking a 9% decrease from the previous quarter but a 12% increase from the same period a year ago. This periodic change is attributed to variances in operating expenses, primarily driven by salary adjustments and increased operational costs associated with technology and compliance.

Year-to-Date Overview

FFB Bancorp reported an operating revenue of $79.32 million over the first nine months of 2025, an increase of 8% compared to $73.74 million in the same period of 2024. The year-to-date results reflect a 7% rise in net interest income, signaling favorable growth despite a challenging economic backdrop.

Asset Quality and Performance Provisions

Credit Quality Metrics

The company held a provision for credit losses of $687,000 in the third quarter, which is a decrease compared to previous provisions and indicates a solid performance regarding asset quality. The allowance for credit losses to total loans ratio was reported at 1.36% as of September 30, 2025.

Future Outlook

Moving forward, FFB Bancorp aims to strengthen its market position by focusing on its core banking services while also exploring innovative product offerings. The company's stable performance metrics highlight resilience in a competitive landscape as it adapts to changing economic environments.

Conclusion

FFB Bancorp remains committed to its strategic growth plans, enhancing its operational efficiency and exploring pathways to capitalize on future growth opportunities. Continued improvements in financial performance and metrics will be key indicators of the company's progress in the upcoming quarters.

Frequently Asked Questions

What are the latest quarterly results for FFB Bancorp?

FFB Bancorp reported net income of $6.24 million for Q3 2025, a rise from the previous quarter but lower than Q3 2024.

How has FFB Bancorp's book value changed?

The book value per common share increased by 6% to $60.04 from the previous quarter, and by 17% compared to last year.

What initiatives has FFB Bancorp undertaken for growth?

The company has focused on hiring and strategic expansions, including appointing a new Chief Banking Officer to strengthen its sales and operational strategies.

What is the asset quality state of FFB Bancorp?

As of September 30, 2025, the allowance for credit losses to total loans ratio stood at 1.36%, indicating a cautious yet resilient approach to credit quality management.

How does FFB Bancorp handle provisions for credit losses?

The bank recorded a provision for credit losses of $687,000 in Q3 2025, reflecting its proactive management of credit risk.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 354

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 26

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 129

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Wuliangye Aims for Global Branding Boost at Panda Event

Updated Category News Views 27

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

Continue Reading
ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Updated Category News Views 50

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 294

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Iceland Seafood International hf Announces Successful Bill Auction

Updated Category News Views 171

Iceland Seafood International hf's Successful Auction Iceland Seafood International hf. has recently completed an offering of 3-month bills under the new series ICESEA 25 0304. This significant milestone reflects the company's ongoing efforts to strengthen its financial position and enhance its market presence. Details of the Bill Auction The total offers for the bills...

Continue Reading
Prolong Pharmaceuticals Showcases PP-007 in Innovative Stroke Study

Updated Category News Views 194

Prolong Pharmaceuticals Highlights Phase 1 Results for Acute Ischemic Stroke Treatment Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical firm, is making waves in the medical community with its recent announcement regarding the preliminary data from the HEMERA-1 trial. This significant study looks into the effects of their lead asset, PP-007, in treating...

Continue Reading
Investors Urged to Join Class Action Against Verve Therapeutics

Updated Category News Views 89

Investors: Consider Joining the Verve Therapeutics Class Action Robbins LLP, a shareholder-rights law firm, is reminding investors about an important window to act in the class action against Verve Therapeutics, Inc. (NASDAQ: VERV). The lawsuit covers individuals and entities that bought or otherwise acquired Verve securities during a defined time frame. Verve is a...

Continue Reading
Top Dividend Stocks for Passive Income Success

Updated Category News Views 246

Building Passive Income Through Smart Investments Creating passive income is a crucial element of a successful early retirement plan. Establishing various sources of passive income is important to reduce the pressure of depending solely on active work for financial support. A key aspect of this strategy is investing in companies known for their above-average dividends,...

Continue Reading
Temperature Monitoring Devices Market Expected to Surge

Updated Category News Views 61

The temperature monitoring devices market experienced a notable surge back in 2024, with projections estimating a compound annual growth rate (CAGR) of 4.5% through to 2034. By the end of that forecast period, sales revenue was set to hit around USD 5.3 billion—a clear indicator of robust expansion in this critical sector. Market Dynamics: Diverse Applications Across...

Continue Reading